Title:The Role of Mitochondria-Targeting miRNAs in Intracerebral Hemorrhage
Volume: 21
Issue: 5
Author(s): Ilgiz Gareev, Ozal Beylerli*, Yanchao Liang, Enzhou Lu, Tatiana Ilyasova, Albert Sufianov, Galina Sufianova, Huaizhang Shi, Aamir Ahmad*Guang Yang*
Affiliation:
- Federal Centre of Neurosurgery, Tyumen, Russia
- Рeoples’ Friendship University of Russia (RUDN
University), 6 Miklukho-Maklaya Street, Moscow, 117198, Russian Federation
- Interim Translational Research Institute, Academic
Health System, Hamad Medical Corporation, Doha, Qatar
- Department of Neurosurgery, The First Affiliated Hospital of Harbin
Medical University, Harbin, 150001, China
- Institute of Brain Science, Harbin Medical University, Harbin,
150001, China
Keywords:
Intracerebral hemorrhage, miRNA, therapeutic target, biomarker, pathogenesis, mitochondria, mitochondrial dysfunction.
Abstract: Non-traumatic intracerebral hemorrhage (ICH) is the most common type of hemorrhagic
stroke, most often occurring between the ages of 45 and 60. Arterial hypertension (AH) is most often
the cause of ICH, followed by atherosclerosis, blood diseases, inflammatory changes in cerebral
vessels, intoxication and vitamin deficiencies. Cerebral hemorrhage can occur by diapedesis or as a
result of a ruptured vessel. AH is difficult to treat, requires surgery and can lead to disability or
death. One of the important directions in the study of the pathogenesis of ICH is mitochondrial dysfunction
and its regulation. The key role of mitochondrial dysfunction in AH and atherosclerosis, as
well as in the development of brain damage after hemorrhage, has been acknowledged. MicroRNAs
(miRNAs) are a class of non-coding RNAs (about 18-22 nucleotides) that regulate a variety of biological
processes including cell differentiation, proliferation, apoptosis, etc., primarily through gene
repression. There is growing evidence to support dysregulated miRNAs in various cardiovascular
diseases, including ICH. Further, the realization of miRNAs within mitochondrial compartment has
challenged the traditional knowledge of signaling pathways involved in the regulatory network of
cardiovascular diseases. However, the role of miRNAs in mitochondrial dysfunction for ICH is still
under-appreciated, with comparatively much lesser studies and investigations reported, than those in
other cardiovascular diseases. In this review, we summarize the up-to-date findings on the published
role miRNAs in mitochondrial function for ICH, and the potential use of miRNAs in clinical settings,
such as potential therapeutic targets and non-invasive diagnostic/prognostic biomarker tools.
